First Platinum GmbH
BioChem Solutions Inc. – Phase 3 trials announced for arthritis, HIV drugs
First Platinum GmbH / Product Launch/Contract Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- 29.Oktober 2007 BIOCHEM SOLUTIONS INC. WKN: A0J36E ISIN: US0909651046 TICKER: NOYC Phase 3 trials announced for arthritis, HIV drugs Miami, FL -- BioChem Solutions Inc. today announced an alliance to complete Phase 3 clinical trials for its Arthromir and Alphamir products, with continuing emphasis on treatment of rheumatoid arthritis, HIV and acute respiratory infections. BioChem has signed a sublicense agreement with Molecular Technologies Ltd. of Nairobi, Kenya, to conduct final trials of the two trademarked drugs, both of which are derived from the patented product Trioxolane. BioChem holds the worldwide master license to produce and distribute all products, of which Arthromir and Alphamir are the first, that incorporate Trioxolane as an active ingredient. The renowned Kenya Medical Institute (KEMRI) will continue to be among several institutions collaborating in the clinical tests. KEMRI, the national agency responsible for all health-science research in that African nation, will primarily assure that the trials continue to comport with international guidelines and regulations governing proper conduct of clinical trials. Phase 3 studies commence when evidence of product effectiveness is shown in Phase 2 trials, as has been the achieved result for both Arthromir and Alphamir. Patients in both study groups have remained symptom-free for four years. The third-phase studies gather more information about safety and efficacy, studying different populations and different dosages as well as observing the consequences of using the drug in combination with other pharmaceuticals. The number of study subjects usually ranges from several hundred to several thousand persons. BioChem ('NOYC' on the Frankfurt Stock Exchange) also holds the global master license to produce and market drugs derived from the patented product Diperoxide. In trials to date, Trioxolane and Diperoxide derivatives have shown significant improvement in the function of the human immune system using a variety of indicators. The use of these drugs has potential in destroying tumor cells and harmful micro-organisms such as bacteria, viruses, parasites and fungi. Treatment is non-toxic and has shown no adverse side effects. Moreover, these drugs reinforce natural immune systems in combating harmful agents and regulating the beneficial production of serotonin, prostaglandin and inflammatory interleukins. BioChem's immediate emphasis is on treatment of patients with systemic conditions such as rheumatoid arthritis, HIV/AIDS and other conditions. Future product development may include a contraceptive vaginal gel to confront sexually transmitted infections, as well as formulations for the treatment of influenza, herpes and acne. This Press Release may contain certain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as 'expects' 'anticipates' 'plans' 'believes' 'scheduled' 'estimates' and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, and stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors beyond the control of management. All forward-looking statements speak only as of the date of this release, or, in the case of any documents incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report. contact: Patti Cooke tel: +1 305-423-7108 fax: +1 305-908-7601 29.10.2007 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden